Curanex Pharmaceuticals Inc

CURX Nasdaq SEC CIK 2025942
Follow Curanex Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$2.8M −195.1% vs same quarter last year
EPS, diluted −$1.86 −148% vs same quarter last year
Operating cash flow −$1.4M +85.2% vs same quarter last year
Operating income −$2.8M −197.4% vs same quarter last year
Net income by quarter
−$145.9K
−$137.6K
−$60.3K
−$954.1K
−$3.1M
−$3.2M
−$3.3M
−$2.8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing